

# Balance sheet and financial position

## Total assets

Total assets decreased from DKK 18,659 million at December 31, 2016, to DKK 18,373 million at December 31, 2017. The decrease was mainly caused by changes in currency, the divestment of Albumedix and the write-down of DKK 120 million on a financial asset related to a guarantee from M&G, partly offset by higher net investments.

## ROIC

Return on invested capital (ROIC), including goodwill, was 25.6%, up 0.5 percentage points from 25.1% in 2016. The increase was mainly a result of a higher EBIT and a lower tax rate, partly offset by higher net investments.

## Invested capital

Invested capital increased from DKK 12,584 million in 2016 to DKK 12,880 million in 2017. This was mainly a result of high net investments, partly offset by the impact of changes in currency.

## Net working capital

Novozymes' net working capital decreased to DKK 2,023 million, down from DKK 2,088 million in 2016, mainly due to an increase in trade payables and a decrease in trade receivables, which has been partly offset by release of deferred income.


## Net interest-bearing debt

Novozymes had net interest-bearing debt of DKK 1,642 million at December 31, 2017, compared with DKK 990 million at December 31, 2016. Net interest-bearing debt was impacted by cash outflows from dividend payments of DKK 1,192 million, stock buybacks of DKK 2,000 million and net investments of DKK 1,668 million, which exceeded cash inflows from operating activities of DKK 4,063 million.


## Net interest-bearing debt-to-EBITDA

Net interest-bearing debt-to-EBITDA was 0.3 at December 31, 2017, compared with 0.2 at December 31, 2016.


### ROIC and invested capital



### Net working capital



### Net interest-bearing debt (NIBD) and net interest-bearing debt-to-EBITDA



# Consolidated balance sheet

## Assets

DKK million	Note	Dec. 31, 2017	Dec. 31, 2016
Intangible assets	2.1, 3.1	2,432	2,737
Land and buildings	2.1, 3.2	2,697	2,931
Plant and machinery	2.1, 3.2	4,019	4,239
Other equipment	2.1, 3.2	562	615
Assets under construction and prepayments	2.1, 3.2	1,648	856
Deferred tax assets	2.6	755	607
Other financial assets		29	151
Investments in associates	3.4	59	73
Other receivables	4.3	35	57
<b>Non-current assets</b>		<b>12,236</b>	<b>12,266</b>
Inventories	4.1	2,586	2,488
Trade receivables	4.2	2,554	2,680
Tax receivables	2.6	135	142
Other receivables	4.3	214	267
Other financial assets		16	4
Cash and cash equivalents	6.6	632	812
<b>Current assets</b>		<b>6,137</b>	<b>6,393</b>
<b>Assets</b>		<b>18,373</b>	<b>18,659</b>

## Liabilities and shareholders' equity

DKK million	Note	Dec. 31, 2017	Dec. 31, 2016
Common stock	5.5	610	620
Currency translation adjustments		(262)	670
Cash flow hedges		45	(41)
Retained earnings		10,861	10,483
<b>Equity attributable to shareholders in Novozymes A/S</b>		<b>11,254</b>	<b>11,732</b>
Non-controlling interests		13	13
<b>Shareholders' equity</b>		<b>11,267</b>	<b>11,745</b>
Deferred tax liabilities	2.6	721	854
Provisions	3.3	159	231
Deferred income	4.4	337	540
Other financial liabilities	5.3	1,312	1,727
<b>Non-current liabilities</b>		<b>2,529</b>	<b>3,352</b>
Provisions	3.3	86	61
Other financial liabilities	5.3	979	200
Trade payables		1,341	1,194
Deferred income	4.4	205	248
Tax payables	2.6	483	437
Other liabilities	4.5	1,483	1,422
<b>Current liabilities</b>		<b>4,577</b>	<b>3,562</b>
<b>Liabilities</b>		<b>7,106</b>	<b>6,914</b>
<b>Liabilities and shareholders' equity</b>		<b>18,373</b>	<b>18,659</b>